# Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer

## TL;DR

This paper explores the role of Sphingosine-1-phosphate in breast cancer and its potential as a new therapeutic target.

## Contribution

The paper provides a comprehensive overview of S1P's mechanisms and therapeutic potential in refractory breast cancer.

## Key findings

- S1P promotes cancer cell proliferation, invasion, and metastasis.
- S1P influences the cancer microenvironment through angiogenesis and immune regulation.
- Targeting S1P signaling offers new therapeutic possibilities for resistant breast cancer.

## Abstract

In recent years, newly emerging therapies, such as immune checkpoint inhibitors and antibody-drug conjugates, have further improved outcomes for breast cancer patients. However, recurrent and metastatic breast cancer often eventually develops resistance to these drugs, and cure is still rare. As such, the development of new therapies for refractory breast cancer that differ from conventional mechanisms of action is necessary. Sphingosine-1-phosphate (S1P) is a key molecule with a variety of bioactive activities, including involvement in cancer cell proliferation, invasion, and metastasis. S1P also contributes to the formation of the cancer microenvironment by inducing surrounding vascular- and lymph-angiogenesis and regulating the immune system. In this article, we outline the basic mechanism of action of S1P, summarize previous findings on the function of S1P in cancer cells and the cancer microenvironment, and discuss the clinical significance of S1P in breast cancer and the therapeutic potential of targeting S1P signaling.